Loading
Life sciences · Journal article
Materials Today Bio · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Inflammatory diseases of the urinary system, including urinary tract infection (UTI), catheter-associated urinary tract infection (CAUTI), interstitial cystitis/bladder pain syndrome (IC/BPS), and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), are associated with high recurrence, complex pathogenesis, and limited therapeutic durability. Conventional treatments are constrained by antimicrobial resistance, biofilm persistence, intracellular bacterial reservoirs, urine washout, urothelial and prostatic barriers, indwelling device surfaces, and heterogeneous neuroimmune inflammatory mechanisms. Nanoparticles provide versatile platforms to address these challenges through tunable physicochemical properties, controlled release, local retention, tissue penetration, and intrinsic material functions. This review summarizes the pathological basis and therapeutic limitations of major inflammatory urinary disorders and discusses recent advances in organic, inorganic, and hybrid nanoplatforms. In infectious diseases, nanoparticles can enhance antibiotic delivery, promote biofilm penetration and intracellular pathogen clearance, and functionalize catheter or stent surfaces with antibacterial, antibiofilm, and anti-encrustation properties. In noninfectious disorders, they support intravesical retention, glycosaminoglycan-layer repair, oxidative-stress modulation, immune regulation, pain-pathway intervention, and prostatic or rectal delivery. Emerging applications in upper UTI and renal inflammatory injury further expand their therapeutic scope. Finally, we discuss current translational barriers, including model fidelity, long-term safety, manufacturing control, clinical evidence, and rational functional integration.